Consensus QuidelOrtho Corporation

Equities

QDEL

US2197981051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 21:00:00 17/04/2026 BST			5-day change	1st Jan Change
12.71 ^USD	+0.20%		-8.23%	-55.50%

04-16	Top Midday Decliners	MT
04-15	QuidelOrtho announces preliminary revenue for the first quarter 2026 and provides update on full-year 2026 guidance	RE

Evolution of the Average Target: QuidelOrtho Corporation

Evolution of the Target Price: QuidelOrtho Corporation

Changes in Analyst Recommendations: QuidelOrtho Corporation

6772080609dff63ac3c81b1f.t32Vtytzelmp64qyY__m1MVRrtBGBwAfA7vTEIyjRCc.2zbszRgEGzzMn_mGDbKwjfNnm7ErVDZ-Ye2_IMv5DErcF8_xEwsDBuve5Q~a9da85008dffcaadaf03b2f2fe8178f6

Analysts' recommendations: QuidelOrtho Corporation

04-10	UBS Adjusts Price Target on QuidelOrtho to $17 From $30, Maintains Neutral Rating	MT
02-12	UBS Adjusts QuidelOrtho Price Target to $30 From $35, Maintains Neutral Rating	MT
01-21	UBS Adjusts QuidelOrtho Price Target to $35 From $31, Maintains Neutral Rating	MT
11-06	UBS Adjusts Price Target on QuidelOrtho to $31 From $26, Maintains Neutral Rating	MT
11-03	QuidelOrtho Receives FDA 510(k) Clearance for VITROS?? Immunodiagnostic Products hs Troponin I Assay	CI
11-03	Quidelortho receives FDA 510(k) clearance for VITROS Immunodiagnostic Products hs Troponin I assay	RE
07/10/25	Citigroup Downgrades QuidelOrtho to Neutral From Buy, Adjusts Price Target to $33 From $40	MT
03/09/25	RBC Raises Price Target on QuidelOrtho to $62 From $60, Keeps Outperform Rating	MT
07/08/25	UBS Cuts Price Target on QuidelOrtho to $26 From $29, Maintains Neutral Rating	MT
08/05/25	UBS Cuts Price Target on QuidelOrtho to $29 From $45, Keeps Neutral Rating	MT
13/02/25	UBS Raises Price Target on QuidelOrtho to $45 From $43, Maintains Neutral Rating	MT
13/02/25	RBC Trims Price Target on QuidelOrtho to $61 From $64, Keeps Outperform Rating	MT
11/12/24	Citigroup Upgrades QuidelOrtho to Buy From Neutral, Raises Price Target to $50 From $44	MT
10/12/24	Jefferies Initiates QuidelOrtho at Hold With $43 Price Target	MT
08/11/24	UBS Cuts Price Target on QuidelOrtho to $43 From $50, Maintains Neutral Rating	MT
08/11/24	RBC Capital Adjusts QuidelOrtho Price Target to $64 From $62, Maintains Outperform Rating	MT
19/09/24	UBS Upgrades QuidelOrtho to Neutral From Sell, Adjusts Price Target to $50 From $42	MT
13/09/24	RBC Lifts Price Target on QuidelOrtho to $62 From $61, Keeps Outperform Rating	MT
05/09/24	QuidelOrtho Shares Rise After Craig-Hallum Upgrade	MT
05/09/24	Craig-Hallum Upgrades QuidelOrtho to Buy From Hold, Adjusts Price Target to $57 From $40	MT
24/06/24	RBC Cuts Price Target on QuidelOrtho to $61 From $68, Keeps Outperform Rating	MT
09/05/24	RBC Cuts Price Target on QuidelOrtho to $68 From $81, Keeps Outperform Rating	MT
04/03/24	UBS Downgrades QuidelOrtho to Sell From Neutral, Adjusts Price Target to $42 From $70	MT
14/02/24	William Blair Downgrades QuidelOrtho to Market Perform From Outperform	MT
14/02/24	Craig-Hallum Downgrades QuidelOrtho to Hold From Buy, Adjusts Price Target to $50 From $158	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	QUIDELORTHO CORPORATION					+142.59%
	SARTORIUS AG					+10.22%
	ECKERT & ZIEGLER SE					+43.9%
	SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.					+66.27%
	REVENIO GROUP OYJ					+37.53%
	VAREX IMAGING CORPORATION					+53.21%
	CELLAVISION AB					+38.92%
	Average					+56.09%
	Weighted average by Cap.					+21.37%